Media headlines about Repligen (NASDAQ:RGEN) have been trending somewhat positive on Sunday, Accern reports. Accern ranks the sentiment of press coverage by analyzing more than twenty million news and blog sources. Accern ranks coverage of companies on a scale of negative one to one, with scores closest to one being the most favorable. Repligen earned a news impact score of 0.19 on Accern’s scale. Accern also assigned news stories about the biotechnology company an impact score of 47.0541374169897 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the stock’s share price in the near term.
Here are some of the news headlines that may have impacted Accern’s rankings:
- Repligen Co. (RGEN) Major Shareholder Sells $233,968.50 in Stock (americanbankingnews.com)
- Repligen Co. (RGEN) Major Shareholder Sells $1,625,615.10 in Stock (americanbankingnews.com)
- Q3 2018 Earnings Estimate for Repligen Co. Issued By Jefferies Financial Group (RGEN) (americanbankingnews.com)
- Repligen Corporation (RGEN) CEO Tony Hunt on Q2 2018 Results – Earnings Call Transcript (seekingalpha.com)
Shares of RGEN opened at $49.27 on Friday. The stock has a market cap of $2.14 billion, a PE ratio of 71.41, a P/E/G ratio of 3.25 and a beta of 0.72. Repligen has a 1-year low of $29.56 and a 1-year high of $50.00.
RGEN has been the topic of several research reports. Zacks Investment Research cut shares of Repligen from a “hold” rating to a “sell” rating in a research report on Tuesday, August 7th. BidaskClub cut shares of Repligen from a “strong-buy” rating to a “buy” rating in a research report on Tuesday, July 31st. Citigroup lifted their target price on shares of Repligen from $45.00 to $56.00 and gave the stock a “buy” rating in a research report on Friday, July 20th. Stephens lifted their target price on shares of Repligen from $50.00 to $55.00 and gave the stock an “average” rating in a research report on Tuesday, July 10th. Finally, ValuEngine upgraded shares of Repligen from a “hold” rating to a “buy” rating in a research report on Thursday, June 28th. One research analyst has rated the stock with a sell rating, two have assigned a hold rating and six have given a buy rating to the company. The company presently has an average rating of “Buy” and an average target price of $46.86.
In other Repligen news, major shareholder Roy T. Eddleman sold 118,850 shares of Repligen stock in a transaction dated Wednesday, May 16th. The shares were sold at an average price of $42.07, for a total value of $5,000,019.50. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO Anthony Hunt sold 16,249 shares of Repligen stock in a transaction dated Monday, May 21st. The stock was sold at an average price of $42.53, for a total transaction of $691,069.97. Following the completion of the transaction, the chief executive officer now directly owns 243,144 shares of the company’s stock, valued at $10,340,914.32. The disclosure for this sale can be found here. Insiders have sold 174,943 shares of company stock worth $7,636,280 in the last three months. 1.40% of the stock is currently owned by insiders.
Repligen Corporation develops, manufactures, and sells products used to enhance the interconnected phases of the biological drug manufacturing process worldwide. It offers Protein A ligands to life sciences companies, which are the binding components of Protein A affinity resins; and growth factor products used to supplement cell culture media.
Read More: Short Selling Stocks and Day Traders
Receive News & Ratings for Repligen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Repligen and related companies with MarketBeat.com's FREE daily email newsletter.